NEW DAWN FOR LIFE SCIENCES IP STRATEGY

59 Pages

This report examines how biotech and pharmaceutical companies are reshaping IP strategies amid regulatory, technological, and legal shifts. Covering areas like CRISPR, mRNA, biosimilars, AI-driven drug discovery, and data monetization, it details challenges in patent landscapes, enforcement, and licensing. The report also explores the convergence of life sciences and tech, implications of the Unified Patent Court, and U.S. policy risks, offering insights on adaptive IP management in an evolving innovation ecosystem.

Join for free to read

White Paper A new dawn for the technology officer

Case Study PHARMACEUTICAL & LIFE SCIENCES

Report Future-Ready Trends in Life Sciences

Case Study Exploring quantum computing use cases for life sciences

More from IAM

Guide Good Practice Guide for Improving Resilience

Report

NEW DAWN FOR LIFE SCIENCES IP STRATEGY

NEW DAWN FOR LIFE SCIENCES IP STRATEGY

You Might Also Like

More from IAM